The current FDA labels for Wegovy, Zepbound and Foundayo each carry a warning about pulmonary aspiration during general anesthesia or deep sedation: rare postmarketing reports of food or fluid still in the stomach despite reported fasting. Professional advice has changed since the first guidance in 2023. The October 2024 multisociety guidance said most patients can continue their GLP-1 before elective surgery, with the decision made jointly by you, the procedure team, the anesthesia team and your prescriber. Do not stop or hold a dose on your own. Tell the team about the medicine early and ask for their instructions in writing.
Why anesthesia teams care about a diabetes and weight medicine
General anesthesia and deep sedation reduce protective reflexes. If the stomach still contains food or liquid, there is a risk that contents travel into the lungs, a complication called pulmonary aspiration. Fasting before a procedure exists to lower that risk.
GLP-1 receptor agonists slow gastric emptying. The Wegovy label says so directly in its pulmonary aspiration warning, section 5.10: the medicine delays gastric emptying, and there have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.
The same wording appears in the Zepbound label (section 5.10) and the Foundayo label (section 5.9). Notice what it is and is not. It is a warning that residual stomach contents have been reported. It is not a statement about how often this happens, and it does not tell you to stop the medicine.
How the advice has changed
This is a topic where advice moved, and old advice is still circulating online. A 2025 peer-reviewed review in SN Comprehensive Clinical Medicine describes the sequence this way.
| When | Source | What it advised |
|---|---|---|
| 2023 | American Society of Anesthesiologists consensus statement | Hold daily-dosed GLP-1 medicines on the day of the procedure and weekly ones one week before. |
| October 2024 | Multisociety clinical practice guidance (AGA, ASMBS, ASA, ISPCOP and SAGES) | Most patients should continue GLP-1 receptor agonists before elective surgery, based on individual risk assessment and shared decision making. |
| 2025 | UK and Australian anaesthesia bodies | Continued the move toward continuation with risk stratification, according to the same review. |
The multisociety guidance was published in several journals, including Clinical Gastroenterology and Hepatology. A peer-reviewed analysis in the Journal of the Endocrine Society quotes its central recommendations: that “most patients should continue taking their GLP-1RAs before elective surgery,” and that use in the perioperative period “should be based on shared decision making by the patient along with procedural, anesthesia, and prescribing care teams.”
The reason for the change was the evidence. The same Journal of the Endocrine Society paper pooled 7 retrospective cohort studies covering 541,408 patients. It reported a combined risk ratio of 1.00 (95% CI 0.76 to 1.30) for elective surgery and 1.10 (95% CI 0.95 to 1.27) for endoscopy, and noted that large real-world databases had not consistently identified a GLP-1 associated risk of aspiration or pneumonia.
How to read those numbers
A risk ratio near 1 means that, in those studies, the outcome was not clearly more common among people taking the medicines. It does not prove that individual patients cannot have residual stomach contents, which is what the label warns about. The studies were also retrospective, meaning they looked back at records rather than assigning people to treatments, so they can miss details like exact dose timing. The honest summary is that two things are true together: the labels carry a warning based on rare reports, and the larger database studies have not shown a clear signal in aggregate. That is the tension the team is trying to manage case by case.
What individualised risk assessment looks like
The guidance asks the teams to assess risk instead of applying one rule to everyone. We have not reproduced a detailed checklist, because we could not open the full text of the guidance from the sources available to us on the day of writing, and we would rather not paraphrase it from memory. The review in SN Comprehensive Clinical Medicine notes that 24-hour clear liquid diets are described as the main alternative for higher-risk patients, permitting items like clear broths, juices and gelatin. Whether you are in that group, and what you should do, is for the team to decide and the written instructions to state.
Things the team may want to know, and that you can volunteer, include:
- Which GLP-1 or tirzepatide product you take, the dose, and the day of the week if it is a weekly injection.
- Whether you are in the early weeks of treatment or just increased the dose, and ask the team whether that changes their plan.
- Any nausea, vomiting, bloating or feeling full for a long time in the days before the procedure.
- Whether you take the medicine for diabetes, since holding it could affect blood sugar control, which is a reason the guidance relies on shared decisions and not a blanket hold.
What to do before an elective procedure
| # | Step | Why |
|---|---|---|
| 1 | Tell the surgeon, proceduralist and anesthesia team about the medicine when you book, not on the day. | The plan can be set in advance. |
| 2 | Ask whether you should continue it, adjust it, or follow a modified diet beforehand. | Advice is individualised. |
| 3 | Ask for the instructions in writing, and tell your prescriber what you were told. | The prescriber should know if the schedule changes. |
| 4 | Follow fasting instructions exactly. | The label’s reports involved people who said they had fasted. Do not shorten the fast. |
| 5 | On the day, repeat the information to the anesthesia team and mention any new stomach symptoms. | Symptoms can change the plan. |
One caution: because the guidance does not say “never hold”, some teams may still ask patients to hold a dose, particularly if their local policy predates the 2024 update. If the instruction differs from what you read here, follow the team treating you and ask them to explain, rather than deciding between sources yourself. Keep your prescriber in the loop.
Urgent and emergency procedures
The label and the guidance discussed here concern elective surgeries and procedures. If you need an urgent or emergency procedure, tell the team about the medicine immediately, including when you last took it. They can plan around it, and nothing about the label’s wording is a reason to delay emergency care.
Does it matter which product I take?
The aspiration warning appears in the sections of the Wegovy, Zepbound and Foundayo labels we reviewed in near-identical language, so the label does not distinguish between the injections and the newer tablet. The guidance was written for GLP-1 receptor agonists as a class, and we did not find a source on the day that separates tirzepatide or orforglipron from it. If you have recently switched products, our article on switching from an injectable to an oral GLP-1 lists timing questions worth raising, and our guide to GLP-1 shot administration and storage explains dosing-day routines that matter when you are working out what day your last dose was.
If you have symptoms that could signal a problem with stomach emptying, our overview of side effects reported in labels and trials sets out what is known, and who should not take an oral GLP-1 covers the warnings and contraindications more broadly.
Common misunderstandings
- “The label says to stop before surgery.” It does not. It describes rare reports and leaves management to clinicians.
- “The guidance says never to hold it.” It says most patients can continue, with shared decisions. Some patients may be advised otherwise.
- “If I fast properly I am safe.” The reports behind the label involved people who reported fasting. Tell the team anyway.
- “This only applies to injections.” The warning appears on the oral product’s label too.
Questions people ask
Does this apply to a dental procedure with local anesthetic?
The label warning refers to general anesthesia or deep sedation. For lighter sedation or local anesthesia, ask the provider performing the procedure what they need to know.
Should I skip a dose to be safe?
Do not make that decision yourself. The guidance describes continuing for most patients, and holding may matter for your blood sugar if you take the medicine for diabetes. Ask the teams and your prescriber.
What if my appointment is soon and nobody has told me anything?
Call the procedure team today and tell them which medicine you take. That call is the single most useful step.
Sources
- U.S. FDA labeling, Wegovy prescribing information, section 5.10, checked 5 October 2026.
- U.S. FDA labeling, Zepbound prescribing information, section 5.10, checked 5 October 2026.
- U.S. FDA labeling, Foundayo prescribing information, section 5.9, checked 5 October 2026.
- Multisociety Clinical Practice Guidance for the Safe Use of Glucagon-like Peptide-1 Receptor Agonists in the Perioperative Period, Clin Gastroenterol Hepatol (PMID 39480373); also published in Surg Obes Relat Dis (PMID 39482213) and Surg Endosc (PMID 39370500).
- Journal of the Endocrine Society, 2025, GLP-1 receptor agonists and peri-procedural aspiration risk.
- SN Comprehensive Clinical Medicine, 2025, 7:313, Perioperative management of GLP-1 receptor agonists.
Medical disclaimer. This article is informational and is not medical advice. Do not stop, hold or change a prescribed medicine before a procedure without instructions from your treating team and your prescriber.
Keep exploring our GLP-1 resources:
